The Terry Fox Foundation awards $27.3 million to six Canadian research teams

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE TERRY FOX FOUNDATION in partnership with the Canadian Institutes of Health Research has awarded $27.3 million in new funding to six Canadian research teams to engineer precision medicines for patients whose cancer has relapsed or for whom current treatments are ineffective or non-existent. The Terry Fox Research Institute teams are conducting research into brain,...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

With the recent FDA approval of daratumumab for high-risk smoldering multiple myeloma, the moment is ripe to revisit the evolution of our understanding of smoldering multiple myeloma. This development not only underscores the growing recognition of early intervention but also invites a broader reflection on the biological insights and therapeutic strategies that have shaped—and continue to shape—this transitional disease state.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login